Myriad Genetics Inc. faces heightened pressure as pivotal genetic testing reimbursement news hits while stocks have been trading down by -45.72 percent
Market Insights For Active Traders
- FY26 revenue guidance was cut to $770M-$790M from $860M-$880M, sharply below the roughly $863.6M street view and driven by weak Q2 trends.
- Management kept adjusted gross margin guidance at 66%-67%, signaling cost discipline even as top-line expectations fall.
- TD Cowen lowered its MYGN price target from $6 to $4, citing weak Q2 results, payer friction, and soft prenatal demand.
- Recent price action shows a collapse from above $5 to under $3, reflecting fast repricing of Myriad Genetics Inc.’s risk profile.
Weekly Update Jul 27 – Jul 31, 2026: On Sunday, August 02, 2026 Myriad Genetics Inc. stock [NASDAQ: MYGN] is trending down by -45.72%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Healthcare industry expert:
Analyst sentiment – negative
Myriad Genetics’ fundamentals show a subscale diagnostics player with attractive 68.8% gross margin but structurally loss‑making operations (EBIT margin −12%, pretax margin −26.3%, ROE about −30%). Revenue growth of ~4–5% CAGR is modest relative to precision diagnostics peers, while FY26 guidance cut underscores limited operating leverage. Balance sheet is adequate (current ratio 2.2, net leverage reasonable, working capital $158M, cash ~$115M), yet negative free cash flow (−$11.5M Q2) and persistent net losses constrain strategic flexibility.
Technically, MYGN is in a capitulation downtrend. The sequence from $5.71 to $3.35 and then $2.91 reflects a rapid breakdown with no meaningful basing, consistent with high‑volume selling post‑guidance cut. The dominant trend is firmly bearish on the weekly chart. For trading, $3.30–3.40 is now a key resistance zone from the first gap‑down pivot; aggressive traders could sell short or write calls against that level, using a tight stop above $3.60.
More Breaking News
- AVGO Stock Holds High Ground As Broadcom Cash Machine Powers On
- Snap Stock Slides As Traders Weigh Ads, Regulation, Insider Sale
- SOFI Stock Slips As Analyst Cuts Price Target To $15
- PURR Stock Tests Support As Hyperliquid Strategies Cash Pile Stands Out
Catalysts are skewed negatively: FY26 revenue guidance was cut by ~10% versus prior outlook and below consensus, with commentary on payer friction and soft prenatal volumes. Sector‑wise, MYGN underperforms broader Healthcare and diagnostics peers on growth, profitability, and capital efficiency, justifying a discount multiple (P/S ~0.33, P/B ~0.8). Near term, resistance is $3.30–3.40, initial support around $2.60; risk‑reward favors an underweight stance with a 6–12 month fair value target near $3.
Quick Financial Overview
Myriad Genetics Inc. just reset expectations in a big way. The company cut its FY26 revenue outlook to $770M-$790M from $860M-$880M, well below the roughly $863.6M consensus, while keeping adjusted gross margin guidance at 66%-67%. That combination tells traders revenue growth is the main problem right now, not basic cost structure or pricing power. Guidance cuts of this size usually trigger a full re-rate, which we are now seeing on the MYGN chart.
On the tape, MYGN traded above $5 early in the week before plunging to the low $3 area, with one session opening around $3.32 and closing near $3.35, then sliding to about $2.91. That is a massive percentage reset in just a few days and shows clear capitulation pressure. Intraday, a 5-minute bar opening near $3.10 and washing down toward roughly $2.81 before closing around $2.86 highlights aggressive selling on the news, with only a modest bounce into the close.
Under the hood, Myriad Genetics Inc. is still posting solid gross margin near 68.8%, with quarterly revenue of about $190.7M and trailing revenue around $824.5M, but profitability is deeply negative. Recent EBITDA of roughly -$26.1M and net income of about -$43.2M underline that MYGN is paying for growth and operations through losses. Returns on equity and assets are sharply negative, while free cash flow of about -$11.5M last quarter shows cash burn, though the $115.2M cash balance and a current ratio of 2.2 give some near-term liquidity cushion.
Conclusion
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.